Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000409434 | SCV000488759 | uncertain significance | Paragangliomas 5 | 2016-06-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000568179 | SCV000674976 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-07-15 | criteria provided, single submitter | clinical testing | The c.-5C>T variant is located in the 5' untranslated region (5’ UTR) of the SDHA gene. This variant results from a C to T substitution 5 bases upstream from the first translated codon. This nucleotide position is not conserved on limited sequence alignment. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV003328582 | SCV004035476 | uncertain significance | not provided | 2023-03-15 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis predicts this variant does not impact splicing. However, in the absence of RNA/functional studies, the actual effect of this sequence change is unknown |
Myriad Genetics, |
RCV000409434 | SCV004045404 | uncertain significance | Paragangliomas 5 | 2023-04-21 | criteria provided, single submitter | clinical testing | This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. |